Bicycle Therapeutics Limited
Meditrina Building
Babraham Research Campus
Cambridge
CB22 3AT
United Kingdom
Tel: 44-0-1223-497-390
Fax: 44-0-7798-791-337
Website: http://www.bicycletherapeutics.com/
136 articles with Bicycle Therapeutics Limited
-
Bicycle Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
8/1/2019
Bicycle Therapeutics plc announced that management will present at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019 at 1:30 p.m. EDT in Boston, MA.
-
BioSpace Movers and Shakers, July 26
7/26/2019
Biotech and pharma companies bolster their executive leadership and boards of directors with this week's appointments. -
Bicycle Therapeutics Enhances Board of Directors
7/24/2019
Appoints pharmaceutical industry veteran Richard N. Kender, MBA, and life sciences financing professional Janice Bourque, MBA
-
Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
7/1/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of a single intravitreal injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor
-
Bicycle Therapeutics Announces Pricing of Initial Public Offering
5/23/2019
Bicycle Therapeutics plc announced the pricing of its initial public offering in the United States of 4,333,333 American Depositary Shares representing 4,333,333 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions.
-
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
-
The company focuses on developing a novel class of drugs called Bicycles. Bicycles are fully synthetic short peptides constrained to form two loops—hence “bi” cycles—that stabilize their structural geometry.
-
BioSpace Movers and Shakers: May 10
5/10/2019
Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more. -
Bicycle Therapeutics Strengthens Clinical Team to Advance Expanding Pipeline
5/9/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, today announced two senior appointments to facilitate its expanding and advancing clinical pipeline. Lisa Mahnke, M.D., Ph.D., joins as Senior Vice President and Head of Clinical.
-
Bicycle Therapeutics Enters Neuroscience Arena through Collaboration with Dementia Discovery Fund
5/7/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, today announced a collaboration with the Dementia Discovery Fund (DDF) to use Bicycle technology for the development of novel therapeutics for neurodegenerative diseases.
-
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
-
4 Biotech Companies Announce IPO Plans
4/29/2019
Four biotech companies recently filed with the U.S. Securities and Exchange Commission their plans for initial public offerings (IPO). Let’s take a look. -
Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumor-targeted Bispecific Bicycles at Peptides Congress
4/24/2019
Bicycle Therapeutics announced that Punit Upadhyaya, Ph.D., Senior Scientist at Bicycle, will present at the 6th Annual Peptides Congress in London.
-
Bicycle Therapeutics and Oxurion Announce Full Enrollment in Phase I Trial for the Treatment of Diabetic Macular Edema
4/24/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, and Oxurion today announced full enrollment of Oxurion’s Phase I trial designed to evaluate the safety of a single injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor.
-
Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting - April 2, 2019
4/2/2019
Bicycle Therapeutics announced that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.
-
Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting
3/29/2019
Bicycle Therapeutics announced that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.
-
Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman - March 18, 2019
3/18/2019
Bicycle Therapeutics announced the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors.
-
Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman
3/18/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, announced the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors.
-
Bicycle Therapeutics to Present on BT5528, a Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumors, at World ADC 2019
3/5/2019
Bicycle Therapeutics announced that Gavin Bennett, Ph.D., Bicycle’s Director of Preclinical Development and Project leader for BT5528, will present at the 9th Annual World ADC Conference in London.
-
BioSpace Movers and Shakers: Feb. 22
2/22/2019
Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more.